
FRUZAQLA® (fruquintinib) resources for healthcare professionals
Access Support
Sample Letter of Medical Necessity

Sample Letter of Medical Appeals

Takeda Oncology Here2Assist® Enrollment Form

Clinical Support
FRUZAQLA MOA Brochure

Patient Profile: Barbara*

Patient Profile: Mark*

FRUZAQLA for US Veterans

Metastatic colorectal cancer ICD-10 codes
We help support the reimbursement process by providing ICD-10 codes.
This list includes commonly used ICD-10 codes for metastatic colorectal cancer:
- C18.0 Malignant neoplasm of cecum
- C18.2 Malignant neoplasm of ascending colon
- C18.3 Malignant neoplasm of hepatic flexure
- C18.4 Malignant neoplasm of transverse colon
- C18.5 Malignant neoplasm of splenic flexure
- C18.6 Malignant neoplasm of descending colon
- C18.7 Malignant neoplasm of sigmoid colon
- C18.8 Malignant neoplasm of overlapping sites of colon
- C18.9 Malignant neoplasm of colon, unspecified
- C19 Malignant neoplasm of rectosigmoid junction
- C20 Malignant neoplasm of rectum
- C21.8 Malignant neoplasm of overlapping sites of rectum, anus and anal canal
- Z12.12 Encounter for screening for malignant neoplasm of colon
- Z12.12 Encounter for screening for malignant neoplasm of rectum
- C78.5 Secondary malignant neoplasm of large intestine and rectum
- C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum
- D37.4 Neoplasm of uncertain behavior of colon
- D37.5 Neoplasm of uncertain behavior of rectum
Takeda Oncology Here2Assist® Patient Support Program
We're here to help your patients with their coverage, financial, and educational resource needs.
Resources to Support Your Patients
Find resources to support your patients taking FRUZAQLA.
aIndividual plans may vary.
*Hypothetical patient. Individual patient results may vary.
†FRUZAQLA should not be used in patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST). Please see full Prescribing Information for more information.1